CAH
Cardinal Health Inc Health Care Wholesale-Drugs, Proprietaries & Druggists' Sundries S&P 500Russell 3000
$250.48Close
$67.9BMarket cap
$182.10 – $257.5552-week range
Nov 5, 2026Next report · before the open
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Near its high 3% below its 52-week high
Cautions
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
3%
1wk
up 0.4%
price change
1mo
up 12.8%
price change
12-month return
up 33%
market up 11% ·
its own up 43%
F-score
6 / 9
Mixed
Altman Z″
-0.22
Elevated risk
P/E
39.6×
price / earnings
PEG
3.27
P/E / EPS growth
P/B
—
price / book
Earnings yield
up 3.6%
EBIT / enterprise value
Cheaper than
64%
of the market · cheap
Revenue growth
up 14%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
—
return on equity
Free cash margin
up 2%
$4.5B FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
1.1×
Interest cover
7.5×EBIT / interest
Piotroski tests
- profitability slipped from last year
- short-term liquidity weakened
- assets working less efficiently
- profitable on its assets
- generating cash from operations
- profits backed by cash
- reduced long-term debt
- no new shares issued
- gross margin widened
Repair signals
- Revenue reaccelerating (-2% then +14%)
Trade setup
ATR%
2.3%
$5.76 a day · 2×ATR $238.96
RS
79 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.1×
vs 50-day average
Up/down volume
0.94
50 sessions
Implied move
6.2%
by Nov 6, 2026 · report Nov 5, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$2.9B as of Jun 30, 2026. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Last reported
Aug 11, 2026
Results reaction
Aug 11, 2026-1% vs market2 sessions after results
Options
$2.1M35.9% IV · activity
Financials
- Gross 4%
- Net 1%
- Free cash 2%
- Cash
- Long-term debt
| FY2021Jun 30, 2021 | FY2022Jun 30, 2022 | FY2023Jun 30, 2023 | FY2024Jun 30, 2024 | FY2025Jun 30, 2025 | FY2026Jun 30, 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $162.5B | $181.3B | $205.0B | $226.8B | $222.6B | $254.2B |
| Gross margin | 4% | 4% | 3% | 3% | 4% | 4% |
| Operating income | $472.0M | -$607.0M | $752.0M | $1.2B | $2.3B | $2.6B |
| Net income | $611.0M | -$938.0M | $330.0M | $852.0M | $1.6B | $1.7B |
| Net margin | 0% | -1% | 0% | 0% | 1% | 1% |
| Earnings per share | $2.08 | -$3.36 | $1.26 | $3.45 | $6.45 | $7.23 |
| Free cash flow | $2.0B | $2.8B | $2.4B | $3.3B | $1.9B | $4.5B |
| Free cash margin | 1% | 2% | 1% | 1% | 1% | 2% |
| Cash | $3.4B | $4.7B | $4.1B | $5.1B | $3.9B | $4.9B |
| Long-term debt | $6.2B | $5.3B | $4.7B | $5.1B | $8.5B | $8.9B |
| Shareholders' equity | $1.8B | -$709.0M | -$3.0B | -$3.2B | -$2.8B | -$2.9B |
| Shares outstanding | 327m | 327m | 327m | 327m | 271m | 271m |
Next report
Nov 5, 2026 · before the open
Expected move The move, either way, the option market prices in through the next scheduled report: the at-the-money straddle for the first expiry that contains it, over the price. It includes the days around the report, so it slightly overstates the report alone. Methodology
±6.2%
$235 – $266 by Nov 6, 2026
Usual move The median, over the company's last four reports, of how far the stock moved either way from the close before the filing to the close of the session after it. Methodology
±6.6%
last 4: -1.5% · -3.7% · +9.4% · +16.0%
Expected against usual The move the options price through this report over the move the last four reports delivered. Above 1 the event is priced bigger than the company's own record; below 1, smaller. A price, not a forecast: it says what protection through the report costs, not which way the stock will go. Methodology
About usual
0.9× the usual move
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $230 – $271 ±8.1% by Nov 27, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 35.9% priced · 25.3% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs less
Positioning
- Premium traded
- $2.1M calls $2.0M · puts $102,896 · latest session
- 0.05× +0.04 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls -940 · puts -876 past week
For options traders: ATM IV 35.9% (+1.3% 1w) · 1m ÷ 3m IV 1.18 · 25Δ skew 0.6 pts · Net GEX $4.3M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 11, 2026 | Annual ↗ | Jun 30, 2026 | 42d |
| Feb 5, 2026 | Quarterly ↗ | Dec 31, 2025 | 36d |
| Oct 30, 2025 | Quarterly ↗ | Sep 30, 2025 | 30d |
| Aug 12, 2025 | Annual ↗ | Jun 30, 2025 | 43d |
| May 1, 2025 | Quarterly ↗ | Mar 31, 2025 | 31d |
| Jan 30, 2025 | Quarterly ↗ | Dec 31, 2024 | 30d |
| Nov 1, 2024 | Quarterly ↗ | Sep 30, 2024 | 32d |
| Aug 14, 2024 | Annual ↗ | Jun 30, 2024 | 45d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 1, 2024 | Quarterly ↗ | Dec 31, 2023 | 32d |
| Nov 3, 2023 | Quarterly ↗ | Sep 30, 2023 | 34d |
| Aug 15, 2023 | Annual ↗ | Jun 30, 2023 | 46d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 1, 2026 | Regulation FD ↗ |
| Aug 11, 2026 | Results · Regulation FD ↗ |
| Aug 11, 2026 | Material agreement · Agreement ended · New obligation ↗ |
| Aug 5, 2026 | Director or officer change ↗ |
| Apr 30, 2026 | Results · Regulation FD ↗ |
| Mar 23, 2026 | Director or officer change · Regulation FD ↗ |
| Mar 5, 2026 | Director or officer change ↗ |
| Feb 5, 2026 | Results · Regulation FD ↗ |
| Jan 13, 2026 | Regulation FD ↗ |
| Nov 6, 2025 | Shareholder vote ↗ |
| Oct 30, 2025 | Results · Regulation FD ↗ |
| Oct 10, 2025 | Material agreement ↗ |